sarepta duchenne muscular dystrophy

News

Duchenne muscular dystrophy, gene therapy

Following second patient death, Duchenne muscular dystrophy families deserve answers about Elevidys

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t getting answers from Sarepta.

Associated Press News on MSN · 2d

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

The Boston Globe · 3d

Sarepta reports second patient death after treatment with Duchenne gene therapy

Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for patients who can no longer walk, following the death of a second person who received the treatment.

STAT8h

What’s next for Sarepta Therapeutics with gene therapy under fire?

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also ...

MedCity News3d

Sarepta Stops Stop Shipments of Muscular Dystrophy Gene Therapy After Second Patient Death

A patient has died after receiving Sarepta Therapeutics’ approved gene therapy for Duchenne muscular dystrophy — the second fatality reported by the company in the past three months.

Why Sarepta Therapeutics (SRPT) Stock Is Down Today

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results